The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable.

about

The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence.Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.

P2860

Q37315628-3FFE9E47-D6A7-4B90-8EA7-47EB93115021 Q37388038-6729716D-4F42-4891-A232-496437DECF65

P2860

The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable.

Item

http://www.wikidata.org/entity/Q43826064

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

The platelet function dose-res ...... revascularization is variable.

@en

The platelet function dose-res ...... revascularization is variable.

@nl

type

Item

label

The platelet function dose-res ...... revascularization is variable.

@en

The platelet function dose-res ...... revascularization is variable.

@nl

prefLabel

The platelet function dose-res ...... revascularization is variable.

@en

The platelet function dose-res ...... revascularization is variable.

@nl

P1476

The platelet function dose-res ...... revascularization is variable.

@en

P2093

D J Kereiakes

http://www.w3.org/2001/XMLSchema#string

D J Moliterno

http://www.w3.org/2001/XMLSchema#string

K Kottke-Marchant

http://www.w3.org/2001/XMLSchema#string

K Patel

http://www.w3.org/2001/XMLSchema#string

M Mueller

http://www.w3.org/2001/XMLSchema#string

M Rosenthal

http://www.w3.org/2001/XMLSchema#string

P J Casterella

http://www.w3.org/2001/XMLSchema#string

P S Teirstein

http://www.w3.org/2001/XMLSchema#string

R E Raymond

http://www.w3.org/2001/XMLSchema#string

S R Steinhubl

http://www.w3.org/2001/XMLSchema#string

P2860

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Rapid platelet-function assay: an automated and quantitative cartridge-based method.

Efficacy of abciximab induced platelet blockade using a rapid point of care assay.

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

P304

497-504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CCD.1320

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2001-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11747189

http://www.w3.org/2001/XMLSchema#string

P921

revascularization

The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable.

about

P2860

P2860

The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921